33 filings
Page 2 of 2
8-K
w0yd9 56jmd
10 Nov 22
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
7:05am
8-K
jeglmbn5rl z9hzcuq
3 Oct 22
Regulation FD Disclosure
7:05am
8-K
pim355mg
28 Sep 22
Regulation FD Disclosure
8:43am
8-K
22d qnk0da79xm
11 Aug 22
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
4:25pm
8-K
bej18z757jur4r
30 Jun 22
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle
7:31am
8-K
c1uq4eti9o
22 Jun 22
Regulation FD Disclosure
5:02pm
8-K
duabr5a 20ugtlk
15 Jun 22
Submission of Matters to a Vote of Security Holders
5:02pm
8-K
kzew40u ugkvmb18
26 May 22
Regulation FD Disclosure
6:04pm
8-K
4eh9iep6wefy3q
18 May 22
Entry into a Material Definitive Agreement
4:06pm
8-K
mj23yn6er3 sir78k
12 May 22
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
4:29pm
8-K
ewxi9c0p35q30sy i5s
23 Mar 22
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
4:21pm
8-K
hah0fmc
24 Nov 21
Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
4:15pm
8-K
8h7eph8 g7v637s6t
2 Nov 21
Amendments to Articles of Incorporation or Bylaws
4:06pm